Redeye endorses ISAB signing a new contract worth approximately SEK 0.6m in the IRS segment. The contractor is a leading nanotechnology company specialized in the development of new inhalable nanoporous particles for drug delivery, which is a fast-growing research area in the pharma industry. We find this interesting and are encouraged to see that ISAB is making further progress in the IRS segment.

Link to the analysis